[Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program NEW YORK and Xianyang, China, The Company’s flagship product is the Xin Ao Xing Oleanolic Acid Capsule, the only SFDA approved OTC drug from the local level to the state level which treats chronic hepatitis B, a condition which affects 10% of the Chinese population. In addition, the]
[Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program NEW YORK and Xianyang, China, The Company’s flagship product is the Xin Ao Xing Oleanolic Acid Capsule, the only SFDA approved OTC drug from the local level to the state level which treats chronic hepatitis B, a condition which affects 10% of the Chinese population. In addition, the]
[For further information: Mr. Weiguo Zhang, Synutra, Inc., 301 840 3888, wzhang@synutra.com Ms. Delia Cannan, Taylor Rafferty, 212 889 4350, synutra@taylor-rafferty.com Synutra Reports Financial Results for the Fourth Quarter and Fiscal Year 2009 Revenues begin to recover for China infant formula company impacted by September 2008 melamine incident; quarterly operating and net losses narrow June 15, 2009, Qingdao, PRC/Rockville, MD,] [___________________________ FORM 8-K CURRENT REPORT June 15, 2009 Date of Report (Date of earliest event reported): SYNUTRA INTERNATIONAL, INC. Delaware 001-33397 13-4306188 (State or other jurisdiction of incorporation) (Commission (IRS Employer Identification No.) 2275 Research Blvd., Suite 500, Rockville, MD 20850 (ZIP Code) (301) 840-3888 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨ ¨]
[For further information: Mr. Weiguo Zhang, Synutra, Inc., 301 840 3888, wzhang@synutra.com Ms. Delia Cannan, Taylor Rafferty, 212 889 4350, synutra@taylor-rafferty.com Synutra Reports Financial Results for the Fourth Quarter and Fiscal Year 2009 Revenues begin to recover for China infant formula company impacted by September 2008 melamine incident; quarterly operating and net losses narrow June 15, 2009, Qingdao, PRC/Rockville, MD,] [___________________________ FORM 8-K CURRENT REPORT June 15, 2009 Date of Report (Date of earliest event reported): SYNUTRA INTERNATIONAL, INC. Delaware 001-33397 13-4306188 (State or other jurisdiction of incorporation) (Commission (IRS Employer Identification No.) 2275 Research Blvd., Suite 500, Rockville, MD 20850 (ZIP Code) (301) 840-3888 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨ ¨]
[AMENDMENT TO LOANOUT AGREEMENT THIS AMENDMENT TO LOANOUT AGREEMENT (“Amendment”) is made and entered into as of May 26, 2009, by and between Skystar Bio-Pharmaceutical Company, a Nevada corporation (the “Company”), and Worldwide Officers, Inc. a California Corporation (the “Lender”). Capitalized terms used herein and undefined shall have the meanings set forth in that certain Loanout Agreement (defined in the] [SKYSTAR BIO-PHARMACEUTICAL COMPANY Room 10601, Jiezuo Plaza No. 4, Fenghui Road South Gaoxin District, Xian Province People’s Republic of China May 26, 2009 Mr. Mark D. Chen Suite 10-64 #9 Jianguomenwai Avenue Beijing, P.R. China 100600 Re: Director Offer Letter Dear Mr. Chen: Skystar Bio-Pharmaceutical Company, a Nevada corporation (the “Company”), is pleased to offer you a director position on]
[AMENDMENT TO LOANOUT AGREEMENT THIS AMENDMENT TO LOANOUT AGREEMENT (“Amendment”) is made and entered into as of May 26, 2009, by and between Skystar Bio-Pharmaceutical Company, a Nevada corporation (the “Company”), and Worldwide Officers, Inc. a California Corporation (the “Lender”). Capitalized terms used herein and undefined shall have the meanings set forth in that certain Loanout Agreement (defined in the] [SKYSTAR BIO-PHARMACEUTICAL COMPANY Room 10601, Jiezuo Plaza No. 4, Fenghui Road South Gaoxin District, Xian Province People’s Republic of China May 26, 2009 Mr. Mark D. Chen Suite 10-64 #9 Jianguomenwai Avenue Beijing, P.R. China 100600 Re: Director Offer Letter Dear Mr. Chen: Skystar Bio-Pharmaceutical Company, a Nevada corporation (the “Company”), is pleased to offer you a director position on]
[Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009 Investments in Infrastructure Expected To Positively Effect Performance This Year New York, New York – May 27, 2009 – Biostar Pharmaceuticals, Inc. (“Biostar” or the “Company”) (OTCBB: BSPM) today reported financial results for the three months ended March 31, 2009. The Company reported revenue of $7,447,664]
[Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009 Investments in Infrastructure Expected To Positively Effect Performance This Year New York, New York – May 27, 2009 – Biostar Pharmaceuticals, Inc. (“Biostar” or the “Company”) (OTCBB: BSPM) today reported financial results for the three months ended March 31, 2009. The Company reported revenue of $7,447,664]
[AMENDMENT TO LOANOUTREEMENT THIS AMENDMENT TO LOANOUTREEMENT (Amendment) is made and entered into of May 26, 2009, by and betweenystar Bio-Pharmaceuticalmpany, a Nevadarporation (thempany), and Worldwide Officers, aliforniarporation (the Lender).pitalized terms used herein and undefined shall have the meanings set forth in that certain Loanoutreement (defined in the Recitals below).] [SKYSTAR BIO-PHARMACEUTICALMPANY Room 10601, Jiezuo Plaza No. 4, Fenghui Road South Gaoxin District, Xian Province Peoples Republic of China May 26, 2009 Mr. Mark D. Chen Suite 10-64 #9 Jianguomenwai Avenue Beijing, P.R. China 100600 Re: Director Offer Letter Dear Mr. Chen:ystar Bio-Pharmaceuticalmpany, a Nevadarporation (thempany), is pleased to offer you a director position on]
[AMENDMENT TO LOANOUTREEMENT THIS AMENDMENT TO LOANOUTREEMENT (Amendment) is made and entered into of May 26, 2009, by and betweenystar Bio-Pharmaceuticalmpany, a Nevadarporation (thempany), and Worldwide Officers, aliforniarporation (the Lender).pitalized terms used herein and undefined shall have the meanings set forth in that certain Loanoutreement (defined in the Recitals below).] [SKYSTAR BIO-PHARMACEUTICALMPANY Room 10601, Jiezuo Plaza No. 4, Fenghui Road South Gaoxin District, Xian Province Peoples Republic of China May 26, 2009 Mr. Mark D. Chen Suite 10-64 #9 Jianguomenwai Avenue Beijing, P.R. China 100600 Re: Director Offer Letter Dear Mr. Chen:ystar Bio-Pharmaceuticalmpany, a Nevadarporation (thempany), is pleased to offer you a director position on]
